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ABSTRACT 
Objective Although water-soluble drugs can be removed by haemofiltration/haemodialysis, morbidity and mortality from 
intoxication with protein-bound drugs remains high. The present study investigates whether albumin dialysis in the form of 
the Molecular Adsorbents Recirculating System (MARS) is effective in removal of protein-bound drugs. 
Design Prospective animal study. 
Setting Surgical research laboratory in a university hospital. 
Subjects Seven female Norwegian Landrace pigs. 
Intervention We studied whether midazolam (97% albumin-bound) and fentanyl (85% alpha-1-acid glycoprotein-bound), 
administered as anaesthetics to pigs with induced acute liver failure, could be removed by MARS dialysis lasting for 4 h. 
Measurements After 4 h of dialysis, total and free anaesthetic concentrations were measured in the blood and dialysate 
from different segments of the MARS circuit. 
Main results Midazolam: total plasma concentrations fell by 47.1±2.1% (in 4 h) across the MARS filter (p<0.01). The 
charcoal component of the system reduced the total dialysate drug concentration by 16.4±2.2% (p<0.05). Free midazolam 
removal followed a similar pattern. Fentanyl: total plasma concentrations fell by 56.1±2.4% (in 4 h) across the MARS filter 
(p<0.01). Clearance of fentanyl from the dialysate by the charcoal was 70±0.7% at 4 h (p<0.001). 
Conclusions The results of the study show that MARS can remove both albumin and other protein-bound drugs efficiently 
from the plasma, and it may have a place for the treatment of patients suffering from intoxication with this class of 
compounds. 
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INTRODUCTION 
The Molecular Adsorbents Recirculating System (MARS) is an extracorporeal device that uses the 
principle of albumin dialysis to remove albumin-bound toxins, and is currently being explored as a 
liver support system [1, 2, 3]; however, the mechanism of action that makes extracorporeal albumin 
dialysis useful in liver failure means that this has the potential to remove a wide range of drugs with 
high albumin binding from the blood. In a recently reported case we demonstrated the efficient removal 
by MARS of an anti-epileptic drug with 90% albumin-binding in a patient of phenytoin toxicity [4]. If 
this applies to other protein-bound substances, the clinical implications would be twofold. Firstly, 
MARS could be of considerable value in overdose/toxicity with protein-binding substances, which 
otherwise cannot be efficiently removed from the body. Secondly, when MARS is being used for liver 
support, it could inadvertently remove drugs (e.g. antibiotics and anti-epileptics), thus lowering their 
plasma concentration and thereby efficacy, unless the drug dosing is adjusted accordingly. 
The effects of MARS therapy on a drug which is strongly albumin-bound in the plasma, may well be 
different from those on a compound that is protein-bound but not significantly albumin-associated 
(which one would not expect to be significantly removed). The opportunity to investigate this was 
provided by a study designed primarily to evaluate the effect of MARS in a porcine model of acute 
liver failure, where a combination of midazolam (97% bound to plasma protein, mainly albumin) and 
fentanyl (80–85% bound to plasma protein, mainly alpha-1-acid glycoprotein) were used to 
anaesthetise the pigs [5]. The present paper describes changes in the plasma concentrations of the two 
drugs during the MARS dialysis, and also examines the underlying mechanisms of removal. 
MATERIALS AND METHODS 
THE ANIMAL MODEL 
The present study was performed by the international liver failure study group at the Surgical Research 
Laboratory, University of Tromsø, Norway, with the approval of the Norwegian Experimental Animal 
Board. Seven Norwegian female Landrace pigs, weighing 25–30 kg (mean±SEM: 27.1±0.5 kg) were 
used. The pigs were kept in the animal department for at least 2 days before the experiments, at a 
temperature of 21±1°C, a relative humidity of 55±10% and with a 12:12-h light/dark cycle. The 
animals were fed with Combi Fri chow (Felleskjøpet, Trondheim, Norway) but were fasted overnight 
prior to the experiment. 
Premedication and anaesthesia are described in detail below. The pigs underwent a tracheostomy, were 
intubated and ventilated (FiO2=0.5) on a volume-controlled respirator (Servo 900, Elema-Schönander, 
Stockholm, Sweden). Tidal volume was adjusted by means of repeated arterial blood gas analyses to 
maintain PaCO2 between 4.5 and 5.0 kPa. Core body temperature was maintained at 38.5±1°C with a 
heating pad and blankets. All animals received 500 ml 0.9% NaCl containing 625 mg of glucose as a 
preoperative load in order to prevent any preoperative dehydration. During the experiment, 0.9% NaCl 
was infused at a rate of 3 ml/kg/h. After the induction of hepatic devascularisation, 50% glucose and 
20% human albumin (Octapharma, Hurdal, Norway) were continuously infused at rates of 0.60 and 
0.66 ml/kg/h, respectively. A dose of 2500 IU heparin was given intravenously to all pigs at the start of 
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the experiment. Subsequently, heparin was given to keep the activated clotting time (ACT)>100 s. 
During MARS treatment, additional heparin was given to keep ACT>180 s. 
Acute liver failure was induced by an end-to-side porta-caval shunt, along with ligation of the hepatic 
arteries. The details of the surgery have been described elsewhere [6, 7]. MARS was started 2 h after 
the hepatic devascularisation and continued for 4 h (i.e. until 6 h post-devascularisation), after which 
the experiments were terminated with an overdose of pentobarbital and potassium chloride. 
ANAESTHESIA 
The pigs were premedicated with an intramuscular injection of ketamine (20 mg/kg) and atropine 
(1 mg). Anaesthesia was induced with an intravenous bolus of 10 mg/kg pentobarbital (Pentobarbital; 
Nycomed Pharma, Oslo, Norway) and 10 mg/kg fentanyl (Leptanal; Janssen Pharmaceutica, Beerse, 
Belgium) and maintained during surgery with a central venous infusion of 4 mg/kg/h pentobarbital, 
0.02 mg/kg/h fentanyl and 0.3 mg/kg/h midazolam (Dormicum; Roche, Basel, Switzerland). 
Anaesthesia was stopped after the liver was devascularised. If there were clinical signs of light 
sedation, small doses of fentanyl and midazolam were given as a bolus. During MARS treatment, the 
animals were kept sedated by a continuous infusion of 0.04 mg/kg/h fentanyl, and 0.6 mg/kg/h 
midazolam, with additional bolus doses given when clinically indicated. 
USE OF MARS 
MARS (Teraklin AG, Rostock, Germany; Fig, 1) is an extracorporeal system utilising albumin dialysis 
which has been described elsewhere [1, 2, 3]. Briefly, it consists of a blood circuit, an albumin circuit, 
and a renal circuit. Blood is dialysed across an albumin-impermeable high-flux dialysis membrane. The 
albumin circuit contains 600 ml of 20% human albumin [i.e. a concentration (200 g/l) five to seven 
times that in the plasma], which passes through the dialysate compartment of the blood dialyser. It 
subsequently undergoes haemo-filtration/dialysis and passage through activated charcoal and anion 
exchange resin columns to remove acquired toxins. As the present study was designed to specifically 
evaluate the role of albumin dialysis in liver failure, haemo-filtration/dialysis was not performed (i.e. 
no removal of free water or water-soluble toxins), and the relevant ports on the circuit were clamped 
off. A blood pump (Stöckert Shiley roller pump, Stöckert Instruments, Munich, Germany) was used to 
run the blood circuit at 150 ml/min, with the albumin dialysate circulated by the MARS pump also at 
150 ml/min. 
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Fig.1 The Molecular Adsorbents Recirculating System (MARS) circuit (with the different segments marked), showing the 
extraction of midazolam and fentanyl at 4 h of treatment from the plasma (in the blood filter column) and from the dialysate 
(by activated charcoal; figures in parentheses are extractions of the free drug) 
SAMPLING 
A central venous blood sample was collected at the start of MARS treatment. Four hours after the start, 
samples were taken from all the different segments of the MARS circuit. Blood samples were collected 
from the inflow and the outflow segments of the MARS filter. Samples of albumin dialysate were 
collected from the different segments of the dialysate circuit (segment 1: between blood and haemo-
filter column; segment 2: between haemo-filter and charcoal column; segment 3: between charcoal and 
anion exchange resin column; segment 4: between resin and blood column; Fig. 1). 
DRUG CONCENTRATION ANALYSIS 
Total and free concentrations of midazolam and fentanyl were measured by high-pressure liquid 
chromatography (HPLC)-coupled mass-spectrometry. 
The HPLC-grade methanol (J.T.Baker, Deventer, Holland), methylclonazepam (F. Hoffmann La-
Roche AG, Switzerland), sulphuric acid and chloroform (Merck-Schuchardt, Germany) were used. 
Water was obtained from a Milli-Q purification system (Millipore, Bedford, Mass.). Standard stock 
solutions were prepared in methanol (15 µM for fentanyl, 1.5 mM for midazolam), and stored at 
−20°C. Plasma, albumin and normal saline standard samples were prepared by addition of stock 
solutions. 
Before analysis, samples underwent ultrafiltration: 150-µl sample was added to Amicon Centrifree 
(Millipore Bedford, Mass.) tubes and centrifuged (1500 g, 12 min, 37°C). The ultrafiltrate was 
collected and stored for less than 1 week at −20°C. For analysis, 100 µ l of sample was mixed with 
sulphuric acid (50 µl 0.05 M), internal standard (50 µl, 1 µM methylclonazepam) and chloroform 
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(1.5 ml). The samples were mixed and then centrifuged (1500 g, 5 min, 20°C), 1 ml of the organic 
phase transferred to a clean tube and evaporated to dryness under a nitrogen gas stream at 35°C. The 
residue was dissolved in 150-µl mobile phase (40% methanol in 5 mM aqueous formic acid). The 
HPLC was performed on a model 2695 (Waters, Milford, Mass.) separation system with a MS C18 
3.5 µm 2.1×10-mm guard column (Waters); triple quadrupole tandem mass spectrometer, Quattro 
Micro (Micromass, Manchester, UK); and data system, MassLynx version 3.5 (Micromass). Ionisation 
mode was positive ion electrospray. Quantitative analysis was performed by multiple reaction 
monitoring (MRM). Injection volume was 3–8 µl with an injection interval of 2.5 min. Autosampler 
temperature was 10°C, desolvation gas temperature 300°C, source temperature 120°C, desolvation gas 
flow 600 l/h, cone gas flow 30 l/h, collision gas pressure 4×10−3 mBar (argon), and ion energies were 
set at 1.0 V for both quadrupoles. 
STATISTICAL ANALYSIS 
Results are expressed as mean±standard error of mean. Student’s t test was used to analyse significance 
of difference between means, and linear regression was used where applicable to determine relationship 
between variables. 
Drug extraction across a filter column was calculated as: Extraction (%) =100 × (Inflow concentration 
minus Outflow concentration)/ Inflow concentration. 
Drug flux across a filter column was calculated as: Flux (nmol/min)=Flow rate × (Outflow 
concentration minus Inflow concentration). 
Plasma flow rate through the blood column of the MARS circuit was calculated as follows: Plasma 
flow rate (L/min) = Blood flow rate × (1-Haematocrit) = 0.15 × (1-Haematocrit). 
A value of p<0.05 was taken to be statistically significant. 
RESULTS 
Plasma total midazolam and fentanyl concentrations at the start of MARS treatment were, respectively, 
1074.6±190.4 and 23.1±3.0 nM. Since the animals were administered boluses of additional doses of 
anaesthetic when they exhibited signs of light sedation, the venous plasma concentrations of both drugs 
(measured from inflowing blood to the MARS system) further increased over the time course of MARS 
usage at 4 h (Table 1). 
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Table 1 Concentrations of total and free midazolam and fentanyl (in nM) at MARS in the plasma in the inflow and outflow 
of Molecular Adsorbents Recirculating System (MARS), and in the albumin dialysate from the different segments of the 
circuit (segment 1: between blood and haemo-filter column; segment 2: between haemo-filter and charcoal column; segment 
3: between charcoal and anion exchange resin column; segment 4: between resin and blood column). Results are expressed 
as mean±SEM. Paired t test was used to test significance of differences between means. Value of p<0.05 was regarded as 
statistically significant 
MIDAZOLAM 
The MARS system extracted 47.1±2.1% of the inflow plasma level of midazolam at 4 h (Fig. 1; 
Table 1). Total midazolam concentration in the dialysate (segment 1) was significantly higher than the 
venous plasma level, with a strong positive correlation between the two (r=0.91, data not shown). The 
charcoal column was the main site of removal of midazolam from the dialysate. Extraction of total 
midazolam by charcoal at 4 h was 16.4±2.2%. The flux of total midazolam across the MARS system 
was −222.6±37.4 nmol/min at 4 h, whereas that across the charcoal column was −185.4±23.3 nmol/min 
(Fig. 2). 
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Fig. 2 The flux of total midazolam and total fentanyl in blood across the MARS circuit, and dialysate across the charcoal 
and anion exchange resin column, at 4 h are shown 
The extraction of free midazolam by the MARS system was 48.4±3.5% of inflow plasma level at 4 h 
(Table 1). Dialysate free drug levels (segment 1) were significantly lower than plasma free levels. The 
free drug extraction across the charcoal column was 25±6.4%. 
There was no significant removal of either the total or free drug across the anion exchange resin. 
FENTANYL 
The MARS system extracted 56.1±2.4% of fentanyl from the inflow plasma at 4 h (Fig. 1; Table 1). 
Total fentanyl concentration in the dialysate (segment 1) was significantly lower than the venous 
plasma level, and there was a strong positive correlation between the two (r=0.90 at 4 h; data not 
shown). As with midazolam, the charcoal column was the main site of removal of fentanyl from the 
dialysate, but with a higher extraction (three to four times greater than that for midazolam). Extraction 
at 4 h was 70±0.7%. The flux of total fentanyl across the MARS system was −5.6±1.1 nmol/min at 4 h, 
and across the charcoal column was −5.6±0.8 nmol/min (Fig. 2). 
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The extraction of free fentanyl by the MARS system from the inflow plasma was 54.6±3.6% at 4 h 
(Table 1). Dialysate free drug levels (segment 1) were significantly lower than plasma free levels. The 
free drug extraction by the charcoal column was 62.4±4%. 
There was no significant removal of total or free drug across the anion exchange resin. 
DISCUSSION 
The present study investigated the role of albumin dialysis, using MARS, in the removal of two 
protein-bound drugs, one of which predominantly binds to albumin (midazolam) and one of which does 
not (fentanyl). Efficient clearance of midazolam (97% albumin-bound [5]) was not unexpected, and the 
strong affinity of midazolam for albumin would explain the higher drug concentration observed in the 
dialysate (200 g/l albumin) compared with that in the venous plasma (~30 g/l albumin). The fact that 
fentanyl (80–85% bound to alpha-1-acid glycoprotein [5]) was removed with equal efficacy was of 
considerable interest and implies that MARS (or albumin dialysis) may have the capacity to remove 
drugs from binding sites on other plasma proteins. While midazolam was removed against a 
concentration gradient (dialysate concentration>plasma concentration), plasma fentanyl levels 
remained higher than those in the dialysate suggesting that it was removed along the concentration 
gradient. 
Both midazolam and fentanyl were primarily cleared from the dialysate by the charcoal filter. This 
observation is supported by the fact that activated charcoal has the ability to adsorb benzodiazepines 
[8] as well as opioids [9], and its oral administration has long been used for the treatment of overdoses. 
Interestingly, the capacity of activated charcoal to remove these drugs from albumin in the dialysate 
indicates that charcoal hemoperfusion could possibly be an effective therapy for such drug toxicities 
[10, 11]. 
Considering that fentanyl is not significantly bound to albumin in the plasma, one might have expected 
a disproportionately large removal of free fentanyl to account for the reduction in total plasma levels; 
however, as can be seen from Table 1, while MARS resulted in a 55% extraction of free drug, this 
cannot account for the total removal of the drug from the plasma. Moreover, analysis of the dialysate 
showed that 80–90% of the fentanyl was present in the albumin-bound form. Taken together, these 
observations imply that fentanyl is removed from the alpha-1-acid glycoprotein in the plasma, and 
binds to the albumin in the dialysate. Fentanyl is not generally bound to albumin in the plasma, but 
there are studies showing that it has the capacity to bind to it and also to erythrocytes [12, 13]. If a 
fairly constant proportion of the total fentanyl concentration is present in the non-protein-bound free 
form, it is conceivable that the binding sites on the MARS membrane take up some of the free drug. 
This in turn would reduce the proportion of free drug present in the plasma leading to release of the 
protein-bound fentanyl. As the membrane-associated albumin gives up its load of fentanyl to the 
albumin in the dialysate, the cycle is repeated and an effective concentration gradient established; thus, 
without actually stripping off fentanyl from alpha-1-acid glycoprotein in the plasma, the effect would 
be the net removal of fentanyl from the plasma. These data support the hypothesis that only the free 
drug is actually being removed by the MARS membrane, with constant re-equilibration of the free and 
bound components in the plasma, without any actual direct removal of the drug from its binding protein 
by the membrane. 
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The main site of removal of both drugs from the dialysate was the column of activated charcoal. The 
calculated flux data suggest that this absorption by the charcoal was almost entirely responsible for 
fentanyl removal from the blood by MARS. In case of midazolam, a higher flux across MARS 
compared with that across the charcoal column suggests that in addition to charcoal, the 
membrane/albumin dialysate contributes to an extent in the removal of this highly albumin-bound drug 
from the blood. 
The present study was not designed to look at the kinetics of drug removal, as the pigs had repeated 
bolus doses of anaesthetics to maintain a stable depth of anaesthesia. The dosage of anaesthetics 
required during MARS was actually higher than that given during the surgery, most likely due to 
removal of the anaesthetic agents. Moreover, the drugs were not administered for long enough to 
achieve steady state; therefore, the drug removal data have been represented as extraction or removal 
rate at 4 hrs into the MARS session. Despite this weakness, this study indicates that better 
understanding is required of drug removal in order to make the necessary modifications to the dosage 
of drugs administered concurrently with MARS treatment. During the use of MARS for liver support, 
the clinician needs to be aware that it might remove some of the other medications the patient is 
receiving for therapeutic purposes. In addition to the groups of drugs mentioned above, a large variety 
of antibiotics are protein-bound (including many which are albumin-bound), as are anti-epileptic drugs. 
Furthermore, the present study shows that many more drugs (not necessarily bound to albumin) can be 
removed which may result in sub-therapeutic blood levels. Awareness of this possible side effect 
should lead to better adjustment of the dosage as well as timing of administration of these drugs. 
The results of this study have other clinical implications as well. Both benzodiazepines and opioids are 
drugs that are commonly used clinically, and can lead to problems related to toxicity or overdosage. In 
the U.S. alone, in 2001 there were 146 deaths due to benzodiazepine and 173 deaths due to opioid 
overdose [14]; however, the availability of effective specific antagonists (flumazenil for 
benzodiazepines and naloxone for opioids) means that in-hospital deaths related to either drug are quite 
rare, and the role of MARS in the therapy of these specific toxicities is limited. Moreover, removal of 
the parent drug (e.g. midazolam) might not necessarily mean that active metabolites (e.g. alpha-
hydroxymidazolam glucuronide) are also adequately removed. Rather, one should consider these two 
drugs as representative of albumin- and other protein-bound drugs that may be effectively removed by 
albumin dialysis. In the setting of a severe drug toxicity not responding adequately to specific 
pharmacological antagonists, this might prove to be an effective way of rapidly reducing circulating 
levels. We have already shown that MARS can effectively clear phenytoin from the plasma in cases of 
toxicity [4]. Overdosage with other protein-bound drugs, such as verapamil and diltiazem (90 and 
80%plasma protein-bound respectively [5]) which have no effective pharmacological antagonists, are 
other clinical settings where MARS might be beneficial. 
Finally, this study provides the first reliable data describing the mechanism by which extracorporeal 
albumin dialysis using MARS may act as a therapeutic tool in protein-bound substance toxicity. The 
results indicate how the system can be modified to improve its efficacy for specific substances. For 
example, in the case of the drugs described, an improved system could be designed by replacing the 
anion exchange resin with an additional activated charcoal column. Such future advances might lead to 
more efficient systems being developed. 
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CONCLUSION 
In conclusion, extracorporeal albumin dialysis using MARS can lead to the efficient removal of both 
albumin-bound and non-albumin-bound substances from the blood. The mechanism of removal is 
probably by uptake of the free drug from the plasma, with constant re-equilibration of the free and 
bound components. The results of this study provide the rationale for exploring the use of 
extracorporeal albumin dialysis for the treatment of intoxication with protein-bound toxins in 
appropriately designed trials. 
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